2846 Chlordiazepoxide Chlordiazepoxide is only found in individuals that have used or taken this drug. It is an anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. Chlordiazepoxide binds to stereospecific benzodiazepine (BZD) binding sites on GABA (A) receptor complexes at several sites within the central nervous system, including the limbic system and reticular formation. This results in an increased binding of the inhibitory neurotransmitter GABA to the GABA(A) receptor.BZDs, therefore, enhance GABA-mediated chloride influx through GABA receptor channels, causing membrane hyperpolarization. The net neuro-inhibitory effects result in the observed sedative, hypnotic, anxiolytic, and muscle relaxant properties. 58-25-3 2712 C16H14ClN3O 299.082540 White powder. 236-236.5°C 2000 mg/L Oral Chlordiazepoxide binds to stereospecific benzodiazepine (BZD) binding sites on GABA (A) receptor complexes at several sites within the central nervous system, including the limbic system and reticular formation. This results in an increased binding of the inhibitory neurotransmitter GABA to the GABA(A) receptor.BZDs, therefore, enhance GABA-mediated chloride influx through GABA receptor channels, causing membrane hyperpolarization. The net neuro-inhibitory effects result in the observed sedative, hypnotic, anxiolytic, and muscle relaxant properties. Hepatic. Route of Elimination: Chlordiazepoxide is excreted in the urine, with 1% to 2% unchanged and 3% to 6% as conjugate. Half Life: 24-48 hours LD50: 537 mg/kg (Oral, Rat) (A308) No indication of carcinogenicity to humans (not listed by IARC). For the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. They cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive. Signs of overdose include respiratory depression, muscle weakness, somnolence (general depressed activity). General supportive measures should be employed, along with immediate gastric lavage. Intravenous fluids should be administered and an adequate airway maintained. Hypotension may be combated by the use of Levophed (norepinephrine) or Aramine (metaraminol). Flumazenil, a specific benzodiazepine-receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be used in situations when an overdose with a benzodiazepine is known or suspected. (L1712) 2009-07-21T20:27:00Z 2014-12-24T20:25:51Z Chlordiazepoxide 3611 Chlordiazepoxide DB00475 true CN=C1CN(=O)=C(C2=CC=CC=C2)C2=C(N1)C=CC(Cl)=C2 C16H14ClN3O InChI=1S/C16H14ClN3O/c1-18-15-10-20(21)16(11-5-3-2-4-6-11)13-9-12(17)7-8-14(13)19-15/h2-9H,10H2,1H3,(H,18,19) InChIKey=ANTSCNMPPGJYLG-UHFFFAOYSA-N 299.755 299.082539792 Exogenous Solid 2.44 HMDB14618 CHEMBL451 10248513 <p>Sternbach, L.H.; US. Patent 2,893,992; July 7,1959; assigned to Hoffmann-LaRoche, Inc.</p>